Navigation Links
BioInformatics, LLC New Report - Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations
Date:6/18/2009

ARLINGTON, Va., June 18 /PRNewswire/ -- BioInformatics, LLC announces the pending release of its newest report, Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations. Designed to provide guidance for life science suppliers selling products that support epigenetic research involving chromosome immunoprecipitation (chIP), this report will help suppliers optimize product offerings and strengthen market position. For this report, BioInformatics, LLC (http://www.gene2drug.com), the premier research and advisory firm serving the life science market, fielded a detailed 56-question survey to scientists worldwide about their current--and planned--areas of study in epigenetics research, usage of related products and preferred suppliers.

The report is scheduled to release in mid-July, and is available at pre-release pricing until July 15, 2009.

Advances enabling faster and cheaper mapping of epigenetic modifications have accelerated discoveries in the field. Since 2007, the National Institutes of Health has supported these efforts with the creation and funding of the Epigenomics Roadmap Initiative, which promotes the discovery of epigenetic markers and the development of new epigenetics-based tools. Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations reviews progress in both of these areas and highlights opportunities for suppliers interested in designing and manufacturing new technologies to support epigenetics researchers. In this study, scientists elaborate on processes and techniques they use to do epigenetics research, problems with protocols and antibodies, changes expected in the time/effort devoted to epigenetics research over the next couple of years and the estimated change in spending on chIP consumables through 2011.

Scientists also provide opinions about suppliers of chIP and non-chIP grade antibodies, and indicate how these products are used, satisfaction with suppliers and desired improvements with each. The following suppliers were provided as choices in the survey:

Abcam (LSE: ABC.L)

Abnova

Active Motif

Affinity Bioreagents (Thermo Fisher Scientific (NYSE: TMO))

Alexis Biochemicals (Enzo Life Sciences) (NYSE: ENZ)

Aviva Systems Biology

BD Biosciences Immunocytometry Systems

BD Biosciences Pharmingen (NYSE: BDX)

Beckman Coulter (NYSE: BEC)

Bethyl Laboratories

BioChemika (Sigma-Aldrich) (NasdaqGS: SIAL)

Biogenesis (MorphoSys)

BioGenex

BIOMOL (Enzo Life Sciences)

BioSource (Life Technologies) (NasdaqGS: LIFE)

Calbiochem (EMD) (NYSE: EMD)

Caltag (life Technologies)

Cell Signaling Technology

Chemicon International (Millipore) (NYSE: MIL)

Covance (NYSE: CVD)

Dako

Diagenode

Dynal Biotech (Life Technologies)

eBioscience

Endogen (Thermo Fisher Scientific)

GE Healthcare (Amersham) (NYSE: GE)

Imgenex

Invitrogen (Life Technologies) (Nasdaq: LIFE)

Jackson ImmunoResearch Laboratories

KPL

LabVision Corporation (Thermo Fisher Scientific)

Miltenyi Biotech

Millipore (NYSE: MIL)

Molecular Probes (Life Technologies)

NeoMarkers (Thermo Fisher Scientific)

Novus Biologicals

Pierce (Thermo Fisher Scientific)

Promega

Quantum Dot (Life Technologies (Invitrogen))

R&D Systems (division of TECHNE Corp., Nasdaq: TECH)

Roche Applied Science

Rockland Immunochemicals

SABiosciences

Santa Cruz Biotechnology

Serotec (MorphoSys)

Sigma-Aldrich (Nasdaq: SIAL)

Upstate (Millipore)

Vector Laboratories

Zymed (Life Technologies (Invitrogen))

"While the majority of the survey respondents are involved in gene regulation studies, changes to the epigenetic state play a central role in many diseases. Cancer is one of the best-studied examples, but many other pathologies, including diabetes, neurological disorders, and aging may have epigenetic contributions," states Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. Dr. Zemlo has been the senior analyst on over 80 syndicated market research reports, and presented findings from Exploring the Epigenetics Market: Opportunities for Product Placement and Innovations at the 2009 Consumer Genetics Show at the Hynes Convention Center in Boston, MA on June 9.

To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/203/.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 43,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

    For more information contact:

    Mary Follin
    Manager, Marketing/Sales
    BioInformatics, LLC
    2111 Wilson Blvd., Suite 250
    Arlington, VA  22201
    703.778.3080 x13 (phone)
    m.follin@gene2drug.com
   http://www.gene2drug.com/


'/>"/>
SOURCE BioInformatics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products
2. BioInformatics, LLC, A Recognized Sponsor of First Annual Consumer Genetics Show in Boston, June 9-11, 2009
3. Childrens Hospital of Philadelphia Earns Highest Combined US News Score in 10 Specialties Ranked by U.S. News & World Report
4. Childrens Named Among the Nations Top 10 Pediatric Hospitals by U.S.News & World Report
5. Stroke survivors report loss of sexual desire, blurred gender roles, anger and fatigue
6. Imagenetix, Inc. Reports Year End Results
7. New Swine Flu Strain Found in Brazil: Report
8. Somanetics Reports Second Quarter Results and Extension of Exclusive Distribution Agreement With Covidien
9. Report: Asbestos Litigation Disaster for Investors Could Be Repeated With Nanotechnology Unless SEC and FASB Close Eight Major Loopholes Now Preventing Honest Disclosures
10. Reportable Food Registry Draft Guidance Published for Comment by FDA
11. New Poll Finds Most Americans Support Including Treatment for Drug and Alcohol Addiction in National Health Care Reform; All Demographics Report Personal Experience With the Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... Vegas, NV (PRWEB) , ... April 25, 2017 ... ... can now choose a modern procedure that achieves results in a fraction of ... in Las Vegas, NV, with Significance Dental Specialists, now offers this revolutionary ...
(Date:4/25/2017)... GA (PRWEB) , ... April 25, 2017 , ... ... their neck and back pain with a reputable physician in their area, announces the ... CRM protects patient information for patients who are looking for reputable physicians to help ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a ... its patient care management module. Using this new feature, sleep physicians can now ... initiated on continuous positive airway pressure (CPAP), oral, or other forms of sleep ...
(Date:4/25/2017)... ... ... Vetoquinol USA® , a world-class developer of veterinarian-approved ... EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin UCII ... The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and joints. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
(Date:4/19/2017)... , April 19, 2017  Vanderbilt University Medical ... patients in Nashville , Tennesse have ... Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. The ... provide long-term reflux control by restoring normal function to ... 65 million people in the United States ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology: